Community Practice Considerations: Emerging Bispecific Antibodies in NHL
Podcast 2: Outcomes of key clinical trials in management of NHL
Post-Test/Evaluation
Exit Survey
Questions marked with a
*
are required
26%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
Which of the following CD20/CD3 bispecific antibodies has been approved for use in patients with refractory/relapsed follicular lymphoma in Europe?
Epcoritamab
Mosunetuzumab
Odronextamab
Glofitamab
For which of the following novel therapies in DLBCL is peripheral neuropathy a commonly reported toxicity?
Polatuzumab vedotin
Loncastuximab tesirine
Tafasitamab
Ibrutinib
Each of the following is a commonly reported adverse event in clinical trials evaluating glofitamab except:
Anemia
Cytokine release syndrome
Hyperphosphatemia
Neutropenia
A 67-year-old man presents with multistation adenopathy, fever, and drenching night sweats. A biopsy reveals he has non-GCB, DEL, normal FISH DLBCL. A PET-CT shows diffuse adenopathy above and below the diaphragm and extranodal involvement of lung, liver, and bone. An end-of-treatment PET-CT scan after six cycles shows CR, but 6 months after remission he develops firm swelling of the left knee and mid back pain. A PET-CT shows destructive mass of left knee as well as vertebral involvement with pathologic compression fracture and multifocal bony recurrence of disease in axial and appendicular skeleton, confirming DLBCL. He is treated with R-ICE and after two cycles shows a mixed response with some areas of progression. How would you treat this patient?
Allogenic stem cell transplant
Lisocabtagene maraleucel
Tazemetostat
Obinutuzumab-lenalidomide
Start
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close